‘Ant-type Insects’ And Expired Ingredients: FDA Warns Bioque Following Inspection
This article was originally published in The Rose Sheet
Agency inspectors observed a range of insanitary conditions and practices at the Blacksburg, Virginia-based manufacturing site that turns out Bioque and Vouray skin-care products, causing the products to be adulterated, according to an FDA warning letter.
You may also be interested in...
ICMAD's recent regulatory workshop offered perspective from FDA's Linda Katz and industry experts on the inspection process for cosmetics facilities under current law. It's clear that FDA inspections can be an ordeal, but that would pale in comparison to challenges that could arise under the proposed Personal Care Products Safety Act.
Agency’s most recently posted warning letters to skin-care marketers include one to PhytoCeuticals for adulterated cosmetics, following an inspection of the company’s manufacturing facility. Osea Internacional and Face Naturals also draw warnings for claims that identify their products as unapproved drugs.
Natural brand Enessa may have to discontinue or relabel its Diminish-Rosacea Treatment, as the name constitutes an unapproved drug claim, FDA suggests in a warning letter. Other claims cited by the agency pertain to cellular repair, collagen synthesis, anti-inflammatory benefits and improved micro-circulation.